dc.contributor
Institut Català de la Salut
dc.contributor
[Nombela P] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. [Lozano R, Olmos D] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain. [Aytes A] Programs of Molecular Mechanisms and Experimental Therapeutics in Oncology (ONCOBell), and Cancer Therapeutics Resistance (ProCURE), Catalan Institute of Oncology, Bellvitge Institute for Biomedical Research, L'Hospitalet de Llobregat, Spain. [Mateo J] Vall d'Hebron Institut d'Oncologia, Barcelona, Spain. Hospital Universitari Vall d'Hebron, Barcelona, Spain. [Castro] Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Center, Madrid, Spain. Medical Oncology Department, Hospital Universitario Quironsalud Madrid, Madrid, Spain.
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Nombela, Paz
dc.contributor.author
Lozano, Rebeca
dc.contributor.author
Aytes, Alvaro
dc.contributor.author
Mateo Valderrama, Joaquim
dc.contributor.author
Olmos, David
dc.contributor.author
Castro, Elena
dc.date.accessioned
2025-10-25T05:37:02Z
dc.date.available
2025-10-25T05:37:02Z
dc.date.issued
2019-05-20T07:44:44Z
dc.date.issued
2019-05-20T07:44:44Z
dc.date.issued
2019-03-12
dc.identifier
Nombela P, Lozano R, Aytes A, Mateo J, Olmos D, Castro E, et al. BRCA2 and Other DDR Genes in Prostate Cancer. Cancers (Basel). 2019;11(3):e352.
dc.identifier
https://hdl.handle.net/11351/4072
dc.identifier
10.3390/cancers11030352
dc.identifier.uri
http://hdl.handle.net/11351/4072
dc.description.abstract
BRCA2; DDR; Prostate cancer
dc.description.abstract
BRCA2; DDR; Càncer de pròstata
dc.description.abstract
BRCA2; DDR; Cáncer de próstata
dc.description.abstract
Germline and somatic aberrations in DNA damage repair (DDR) genes are more prevalent in prostate cancer than previously recognized, with BRCA2 as the most commonly altered gene. Germline mutations in BRCA2 have been linked to poor prognosis when patients are managed under the protocols currently approved for prostate cancer. The impact of germline mutations in other DDR genes beyond BRCA2 remain unclear. Importantly, a quarter of prostate cancer patients identified as germline mutation carriers lack a family history of cancer. The clinical implications of somatic DDR defects are yet to be elucidated. Poly ADP-ribose polymerase (PARP) inhibitors and platinum-based chemotherapy have proven to be effective in the treatment of other tumor types linked to BRCA1 and BRCA2 alterations and several trials are currently evaluating their efficacy in prostate cancer. Here, we summarize the available evidence regarding the prevalence of somatic and germline DDR defects in prostate cancer; their association with clinical outcomes; the trials assessing the efficacy of new therapies that exploit DDR defects in prostate cancer and briefly discuss some uncertainties about the most appropriate management for these patients.
dc.description.abstract
Supported by grants CM17/00221, PI16/01070, CP15/00090 and PI16/01565 from the Instituto de Salud Carlos III, PC170510P2 from the U.S. Department of Defense, W81XWH-18-1-0193 from the U.S. Department of Defense, RYC-2015-18625 from the Ministerio de Economía y Competitividad and Young Investigator Awards from the Prostate Cancer Foundation
dc.format
application/pdf
dc.relation
Cancers;11(3)
dc.relation
https://www.mdpi.com/2072-6694/11/3/352
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Pròstata - Càncer- Aspectes genètics
dc.subject
ADN - Reparació
dc.subject
DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms
dc.subject
CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Fanconi Anemia Complementation Group Proteins::BRCA2 Protein
dc.subject
PHENOMENA AND PROCESSES::Genetic Phenomena::DNA Damage
dc.subject
PHENOMENA AND PROCESSES::Chemical Phenomena::Biochemical Phenomena::DNA Repair
dc.subject
Other subheadings::Other subheadings::Other subheadings::/genetics
dc.subject
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas de grupos de complementación de la anemia de Fanconi::proteína BRCA2
dc.subject
FENÓMENOS Y PROCESOS::fenómenos genéticos::daño del ADN
dc.subject
FENÓMENOS Y PROCESOS::fenómenos químicos::fenómenos bioquímicos::reparación del ADN
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/genética
dc.title
BRCA2 and Other DDR Genes in Prostate Cancer
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
